<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677998</url>
  </required_header>
  <id_info>
    <org_study_id>W20_181</org_study_id>
    <nct_id>NCT04677998</nct_id>
  </id_info>
  <brief_title>A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis</brief_title>
  <official_title>A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Mark's Hospital Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Edouard Herriot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario de Alicante</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of a personalized&#xD;
      surveillance and intervention protocol for duodenal and gastric polyposis in patients with&#xD;
      familial adenomatous polyposis (FAP)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with FAP are not only at risk of developing colorectal adenomas but also at high&#xD;
      risk of developing duodenal adenomas. In 30% to 92% of FAP patients duodenal adenomas are&#xD;
      detected, with a lifetime risk approaching 100%. Of these duodenal adenomas, only a small&#xD;
      proportion develops into duodenal cancer, with a prevalence of approximately 5-10% in FAP&#xD;
      patients.&#xD;
&#xD;
      Endoscopic surveillance is nowadays the standard of care to prevent FAP patients from&#xD;
      developing duodenal cancer. The severity of duodenal polyposis is assessed using the&#xD;
      Spigelman classification system. This classification is based on the number, size, histology,&#xD;
      and grade of dysplasia of the duodenal adenomas, resulting in a score varying from 0-IV,&#xD;
      guiding surveillance intervals and treatment.&#xD;
&#xD;
      Concerns are rising on the accuracy of the Spigelman score as predictor for duodenal cancer,&#xD;
      especially for ampullary cancer. Over the past years, multiple studies demonstrated&#xD;
      limitations of this staging system including the fact that this classification does not&#xD;
      adequately predict duodenal/ampullary cancer and does not guide endoscopic or surgical&#xD;
      interventions. A clear endoscopic intervention protocol is needed, not only to prevent the&#xD;
      development of cancer but also to prevent the need for duodenal surgery, since these surgical&#xD;
      procedures are associated with high complication and mortality rates.&#xD;
&#xD;
      With this study, the investigators aim to evaluate a personalized surveillance and&#xD;
      intervention protocol for the duodenum and stomach with the goal to prevent the development&#xD;
      of advanced neoplasia (AN) by endoscopically removing lesions before they progress to AN.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Advanced neoplasia</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence of advanced neoplasia defined as adenomas ≥15mm, high grade dysplasia (HGD) and/or duodenal/ampullary cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrences after different endoscopic intervention techniques</measure>
    <time_frame>Analysis at 2 years and 5 years</time_frame>
    <description>Incidence of recurrences after endoscopic interventions after en bloc/piecemeal resection and different techniques such as cold snare polypectomy or endoscopic mucosal resection with or without lifting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of endoscopic interventions</measure>
    <time_frame>Analysis at 2 years and 5 years</time_frame>
    <description>Incidence of lesions not amenable to endoscopic removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy optical diagnosis</measure>
    <time_frame>Analysis at 2 years and 5 years</time_frame>
    <description>The ability of endoscopists to optically diagnose duodenal and gastric lesions. Sensitivity and specificity for optically diagnose high-grade dysplasia in the stomach and duodenum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Analysis at 2 years and 5 years</time_frame>
    <description>Incidence of endoscopy related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surveillance burden</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Surveillance burden (number of endoscopies for each patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence of surgical interventions</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Familial Adenomatous Polyposis</condition>
  <arm_group>
    <arm_group_label>Personalized surveillance and intervention protocol</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Personalized surveillance and intervention protocol</intervention_name>
    <description>This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 3-6 months and 5 years, depending on severity of polyposis and performed endoscopic interventions.</description>
    <arm_group_label>Personalized surveillance and intervention protocol</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with FAP treated at one of the participating centers will be assessed for&#xD;
        eligibility.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of FAP, at least one of following: genetic diagnosis (proven APC germline&#xD;
             mutation) and/or clinical diagnosis (&gt;100 colorectal adenomas in combination with a&#xD;
             positive family history of FAP)&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Endoscopic removal of all polyps with an indication for removal not possible/feasible&#xD;
&#xD;
          -  Gastric or duodenal cancer at baseline endoscopy&#xD;
&#xD;
          -  Need for surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelien Dekker, MD, PhD</last_name>
      <phone>0031205661260</phone>
      <email>e.dekker@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Arthur Aelvoet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof. Evelien Dekker, MD, PhD</investigator_full_name>
    <investigator_title>Prof. dr. Evelien Dekker, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Endoscopic surveillance</keyword>
  <keyword>Endoscopic interventions</keyword>
  <keyword>Personalized care</keyword>
  <keyword>Gastrointestinal neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

